ChiCTR2500113619 版本V1.0 版本创建时间2025/12/01 15:41:50 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500113619 

最近更新日期:

Date of Last Refreshed on:

2025-12-01 15:41:21 

注册时间:

Date of Registration:

2025-12-01 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

肌少症指数动态发展与脓毒症老年患者预后关系的研究

Public title:

Association between Dynamic Changes in Sarcopenia Index and Prognosis of Elderly Patients with Sepsis?

注册题目简写:

English Acronym:

研究课题的正式科学名称:

肌少症指数动态发展与脓毒症老年患者预后关系的研究

Scientific title:

Association between Dynamic Changes in Sarcopenia Index and Prognosis of Elderly Patients with Sepsis?

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

陈界宇 

研究负责人:

陈界宇 

Applicant:

Chen Jieyu 

Study leader:

Chen Jieyu 

申请注册联系人电话:

Applicant telephone:

+86 138 8034 5776

研究负责人电话:

Study leader's
telephone:

+86 138 8034 5776

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

runningchen2022@163.com

研究负责人电子邮件:

Study leader's E-mail:

runningchen2022@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国四川省成都市金牛区蓉都大道天回段270号,西部战区总医院

研究负责人通讯地址:

中国四川省成都市金牛区蓉都大道天回段270号,西部战区总医院

Applicant address:

Western Theater General Hospital 270 Tianhui Section, Rongdu Avenue Jinniu District, Chengdu Sichuan Province, China

Study leader's address:

Western Theater General Hospital 270 Tianhui Section, Rongdu Avenue Jinniu District, Chengdu Sichuan Province, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中国人民解放军西部战区总医院

Applicant's institution:

Western Theater General Hospital

研究负责人所在单位:

中国人民解放军西部战区总医院

Affiliation of the Leader:

Western Theater General Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2025EC3-ky014

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国人民解放军西部战区总医院伦理委员会

Name of the ethic committee:

Ethics Committee of Western Theater General Hospital, People's Liberation Army of China

伦理委员会批准日期:

Date of approved by ethic committee:

2025-03-21 00:00:00

伦理委员会联系人:

苗艺凡

Contact Name of the ethic committee:

Miao Yifan

伦理委员会联系地址:

中国四川省成都市金牛区蓉都大道天回段270号,西部战区总医院

Contact Address of the ethic committee:

Western Theater General Hospital, 270 Tianhui Section, Rongdu Avenue Jinniu District, Chengdu Sichuan Province, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 28570332

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中国人民解放军西部战区总医院

Primary sponsor:

Western Theater General Hospital

研究实施负责(组长)单位地址:

中国四川省成都市金牛区蓉都大道天回段270号,西部战区总医院

Primary sponsor's address:

Western Theater General Hospital 270 Tianhui Section, Rongdu Avenue Jinniu District, Chengdu Sichuan Province, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川省

市(区县):

成都市

Country:

China

Province:

Sichuan

City:

Chendu

单位(医院):

中国人民解放军西部战区总医院

具体地址:

中国四川省成都市金牛区蓉都大道天回段270号,西部战区总医院

Institution
hospital:

Western Theater General Hospital

Address:

Western Theater General Hospital 270 Tianhui Section, Rongdu Avenue Jinniu District, Chengdu Sichuan Province, China

经费或物资来源:

自筹

Source(s) of funding:

Self-financing

研究疾病:

肌少症 脓毒症  

Target disease:

Sarcopenia Sepsis

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

回顾性研究 

Study phase:

Retrospective study

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

本研究旨在记录,分析老年(年龄>65岁)脓毒症患者肌少症指数(SI)的动态变化轨迹,并探究其与180天死亡率的关系,为早期风险分层和个体化干预提供依据。  

Objectives of Study:

This study aims to identify distinct dynamic trajectories of the Sarcopenia Index (SI) using group-based trajectory modeling (GBTM) in elderly patients (aged >65 years) with sepsis and to investigate their association with 180-day mortality, providing a basis for early risk stratification and personalized intervention strategies.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)年龄>65岁的住院患者。 (2)符合脓毒症3.0诊断标准(感染+SOFA评分≥2分)。

Inclusion criteria

(1) Hospitalized patients aged >65 years. (2) Meeting Sepsis 3.0 diagnostic criteria (infection + SOFA score ≥ 2).

排除标准:

(1)入院时间小于24小时; (2)年龄小于 65岁。 (3)数据缺失无法评估者(SI评估小于三次)。 (4)合并有严重的肾功能不全者。

Exclusion criteria:

(1) Hospital stay less than 24 hours. (2) Age less than 65 years. (3) Patients with missing data that preclude evaluation (fewer than three Sarcopenia Index (SI) assessments) (4) Patients with severe renal insufficiency.

研究实施时间:

Study execute time:

From 2025-03-21 00:00:00 To 2025-08-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-03-21 00:00:00 To 2025-08-31 00:00:00

干预措施:

Interventions:

组别:

低水平组

样本量:

122

Group:

Low-Level Group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

高水平组

样本量:

88

Group:

High-Level Group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

四川 

市(区县):

成都 

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

西部战区总医院 

单位级别:

三甲 

Institution
hospital:

The General Hospital of Western Theater Command

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

180天全因死亡率

指标类型:

主要指标

Outcome:

180-day All-cause Mortality

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肌少症指数动态轨迹

指标类型:

次要指标

Outcome:

Dynamic Trajectories of Sarcopenia Index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

急性生理学与慢性健康状况评分II

指标类型:

次要指标

Outcome:

Acute Physiology and Chronic Health Evaluation II (APACHE II)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Barthel指数

指标类型:

次要指标

Outcome:

Barthel Index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

序贯器官衰竭评估评分

指标类型:

次要指标

Outcome:

Sequential Organ Failure Assessment (SOFA) Score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血红蛋白

指标类型:

次要指标

Outcome:

Hemoglobin

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

超敏C反应蛋白

指标类型:

次要指标

Outcome:

High-sensitivity C-reactive Protein

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

降钙素原

指标类型:

次要指标

Outcome:

Procalcitonin

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

白蛋白

指标类型:

次要指标

Outcome:

Albumin

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

白细胞计数

指标类型:

次要指标

Outcome:

White blood cell count

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血小板计数

指标类型:

次要指标

Outcome:

platelet count

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

D-二聚体

指标类型:

次要指标

Outcome:

D-dimer

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血压

指标类型:

次要指标

Outcome:

blood pressure

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心率

指标类型:

次要指标

Outcome:

heart rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

呼吸频率

指标类型:

次要指标

Outcome:

respiratory rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

体温

指标类型:

次要指标

Outcome:

body temperature

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

既往病史

指标类型:

次要指标

Outcome:

Past Medical History

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

高血压

指标类型:

次要指标

Outcome:

Hypertension

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心脑血管病

指标类型:

次要指标

Outcome:

cardiovascular and cerebrovascular diseases

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

糖尿病

指标类型:

次要指标

Outcome:

diabetes

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

慢性阻塞性肺疾病

指标类型:

次要指标

Outcome:

COPD

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

年龄

指标类型:

次要指标

Outcome:

Age

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

性别

指标类型:

次要指标

Outcome:

Sex

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 65 years
最大 Max age 100 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

不适用

Randomization Procedure (please state who generates the random number sequence and by what method):

Not applicable

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

本研究为回顾性观察性研究,所有数据均来源于患者的电子病历系统,包含敏感的个人健康信息。为严格保护患者隐私、遵守医疗机构数据安全管理规定以及本研究伦理审查协议的要求,原始数据仅限本研究团队在授权范围内用于本次分析,不对外公开。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

This study is a retrospective observational study. All data were derived from patients' electronic medical record systems and contain sensitive personal health information. To strictly protect patient privacy, comply with institutional data security management regulations, and adhere to the requirements of this study's ethical review protocol, the raw data are accessible only to the research team for the purpose of this analysis under authorized access and will not be made publicly available.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

利用Excel等电子采集和管理系统(Electronic Data Capture, EDC)进行数据采集和管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Use Electronic Data Capture (EDC) system, like Excel software for data collection and management

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-12-01 15:41:21